Cassava Sciences terminates $100M SVB ATM, enters $200M ATM with JonesTrading

FILANA THERAPEUTICS, INC.

Terminated SVB Securities ATM agreement effective May 1, 2023; no shares ever sold under that facility.
Entered new Capital on Demand Sales Agreement with JonesTrading for up to $200M aggregate offering price.
New ATM replaces prior program; shares sold via 'at the market' offerings under new shelf registration statement S-3.
JonesTrading receives commission up to 3% of gross proceeds; company reimburses certain expenses.
No obligation to sell shares; company can set minimum price and suspend or terminate offering.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

FILANA THERAPEUTICS, INC. terminated SVB Sales Agreement with SVB Securities LLC (f/k/a SVB Leerink LLC) valued at up to $100,000,000 (effective 2023-05-01).

Action: termination
Agreement: atm program
Counterparty: SVB Securities LLC (f/k/a SVB Leerink LLC)
Value: up to $100,000,000
Effective: 2023-05-01

Exact text from the filing

On April 26, 2023, the Company provided SVB with notice of termination of the SVB Sales Agreement, effective May 1, 2023.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

FILANA THERAPEUTICS, INC. entered into Capital on DemandTM Sales Agreement with JonesTrading Institutional Services LLC valued at up to $200,000,000 (effective 2023-05-01).

Action: entry
Agreement: atm program
Counterparty: JonesTrading Institutional Services LLC
Value: up to $200,000,000
Effective: 2023-05-01

Exact text from the filing

On May 1, 2023, the Company entered into a Capital on DemandTM Sales Agreement (the “Sales Agreement”) with JonesTrading Institutional Services LLC, as agent (“Agent”), pursuant to which the Company may offer and sell, from time to time through or to the Agent, shares of the Company’s common stock, par value $0.001 per share (the “Shares”), having an aggregate offering price of up to $200,000,000 (the “Offering”).

View on SEC.gov

Browse all material agreements →

FILANA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001493152-23-015041

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.